Advanced Prenatal Therapeutics, Inc. (APT)
APT is developing a Breakthrough Medical Device and screening test specifically designed to treat preeclampsia, a leading cause of maternal and fetal death WW.
- Stage Product In Development
- Industry Medical Devices and Equipment
- Location Laguna Hills, CA, USA
- Currency USD
- Founded September 2012
- Employees 4
- Incorporation Type C-corp
- Website advancedprenatal.com
Company Summary
APT is developing a Targeted Apheresis Column for Preeclampsia (TAC- PE) to be used to specifically and safely remove pathogenic factors associated with preeclampsia, including sFlt-1, from the blood of pregnant mothers. Removing these factors could lead to prolonged pregnancy, improved fetal outcomes, and decreased risk associated with preterm birth. APT's TAC-PE could become the standard of care for treating this virtually unmet need.
Team
-
James Smith, Ph.D.President / CEO
Dr. Smith has over 18 years of experience in regulatory affairs and development of novel technologies from concept through commercialization. He is experienced in all aspects of regulatory affairs, quality and data management systems, supervision of R&D, development of new product specifications, and with evaluating and registering medical drug and device product lines. Ph.D. in Pharmacology and Toxicology from University of California, Irvine.
-
Henry Smith, Ph.D.Chairman of the Board
Dr. Smith has over 40 years of experience in the healthcare industry. Co-founder of several biotechnology companies and medical laboratories including NanoSmart Pharmaceuticals, Epinex Diagnostics, Allied Biotechnology International, and Associated Reference Laboratories. Senior management in medical reference laboratories including Specialty Labs and BioScience Laboratories. Ph.D. Immunology from University of Leeds Medical School, England.
-
VP Business Development
Mr. Thiel has over 15 years experience in management positions in the biotechnology industry providing services in business development, fund raising, investor relations, marketing and PR for early-stage development companies. Mr. Thiel received his B.S. in Business from Miami University, Ohio, with a concentration in international business at Universidad de Las Americas, in Puebla, Mexico.
-
Jacqueline MoralesVP Operations
Ms. Morales has over 10 years experience in biotech sector supporting new product development. She has expertise in designing, auditing, and implementing ISO quality systems, preparing domestic and international regulatory filings, managing clinical laboratory operations, and overseeing marketing and corporate communications projects. Certificate in Medical Product Development, BS in Biological Sciences, minor Business Management from UC Irvine.
Advisors
-
Nihar Niyak, D.V.M., Ph.D.UnconfirmedVijay Mahant, M.S., Ph.D.Unconfirmed
Previous Investors
-
FoundersUnconfirmedPrivate Accredited InvestorsUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.